Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
Office: bldg. E35/186
Kamenice 753/5
625 00 Brno
Phone: | +420 532 23 5494, +420 736 722 290 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 73
2023
-
Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu.
Year: 2023, type: Conference abstract
2022
-
. Drug repurposing for venetoclax-resistant acute myeloid leukemia.
Year: 2022, type: Conference abstract
-
A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome
International Journal of Molecular Sciences, year: 2022, volume: 23, edition: 2, DOI
-
Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells.
Year: 2022, type: Conference abstract
-
CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation.
Year: 2022, type: Conference abstract
-
Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML
Year: 2022, type: Conference abstract
-
Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models.
Year: 2022, type: Conference abstract
-
Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing
Year: 2022, type: Conference abstract
-
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells
Frontiers in Cell and Developmental Biology, year: 2022, volume: 10, edition: February 2022, DOI
-
Prediction of novel treatment options for CLL and AML cells based on drug repurposing.
Year: 2022, type: Conference abstract